New GERD drug fexuprazan goes Head-to-Head with standard treatment
NCT ID NCT07326904
First seen Jan 11, 2026 · Last updated Jun 18, 2026 · Updated 25 times
Summary
This study tested whether fexuprazan, a new medication, can relieve heartburn and acid regurgitation in adults with GERD as effectively as the commonly used drug esomeprazole. 145 participants took either fexuprazan or esomeprazole once daily for 4 weeks (up to 8 weeks if needed) and reported their symptoms. The goal was to see if fexuprazan offers similar symptom relief and safety.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTRO OESOPHAGEAL REFLUX DISEASE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Islam Cempaka Putih Jakarta Hospital
Jakarta Pusat, DKI Jakarta, 10510, Indonesia
-
Menteng Mitra Afia Jakarta Hospital
Jakarta Pusat, DKI Jakarta, 10340, Indonesia
-
University of Indonesia Hospital
Depok, West Java, 16424, Indonesia
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.